Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant
Source: OncLive, April 2024
Michael R. Migden, MD, dermatologist, professor, Department of Dermatology, Division of Internal Medicine and Head and Neck Surgery, Division of Surgery, and program director, ACGME Fellowship:Micrographic Surgery and Dermatologic Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy data from the phase 1b/2 ARTACUS trial (NCT04349436) evaluating the oncolytic immunotherapy RP1 in patients with advanced non-melanoma cutaneous malignancies who underwent prior solid organ transplant.
Findings presented at the 2024 AACR Annual Meeting showed that evaluable patients administered single-agent RP1 (n = 23) experienced an overall response rate (ORR) of 34.8%, including a complete response rate of 21.7% and a partial response of 13.0%; 4.3% of patients achieved stable disease. The disease control rate was 39.1% with the agent. Moreover, 60.9% of patients experienced progressive disease.
Among the 8 responders, 6 patients had cutaneous squamous cell carcinoma, and 2 patients had Merkel cell carcinoma. At baseline, 6 responders had locally advanced disease, and 2 patients had metastatic disease.